{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:00:05Z","timestamp":1791270005980,"version":"4.1.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,9,1]]},"DOI":"10.1097\/qai.0b013e318227fc34","type":"journal-article","created":{"date-parts":[[2011,6,21]],"date-time":"2011-06-21T02:41:18Z","timestamp":1308624078000},"page":"23-31","source":"Crossref","is-referenced-by-count":162,"title":["Unnecessary Antiretroviral Treatment Switches and Accumulation of HIV Resistance Mutations; Two Arguments for Viral Load Monitoring in Africa"],"prefix":"10.1097","volume":"58","author":[{"given":"Kim C E","family":"Sigaloff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raph L","family":"Hamers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole L","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cissy","family":"Kityo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Siwale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prudence","family":"Ive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariette E","family":"Botes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishor","family":"Mandaliya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Wellington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akin","family":"Osibogun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy S","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mich\u00e8le","family":"van Vugt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias F","family":"Rinke de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-4-20210131","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1086\/431199","article-title":"Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature.","volume":"41","author":"Ivers","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R4-4-20210131","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1365-3156.2009.02309.x","article-title":"Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria.","volume":"14","author":"van Oosterhout","year":"2009","journal-title":"Trop Med Int Health"},{"key":"R5-4-20210131","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/QAD.0b013e3283262a78","article-title":"Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda.","volume":"23","author":"Reynolds","year":"2009","journal-title":"AIDS"},{"key":"R6-4-20210131","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1097\/QAD.0b013e32830e4cd8","article-title":"Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa.","volume":"22","author":"Mee","year":"2008","journal-title":"AIDS"},{"key":"R7-4-20210131","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/QAI.0b013e318186eb18","article-title":"CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy.","volume":"49","author":"Moore","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R8-4-20210131","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1473-3099(09)70136-7","article-title":"Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis.","volume":"9","author":"Gupta","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"R10-4-20210131","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jviromet.2009.11.011","article-title":"Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1.","volume":"163","author":"Wallis","year":"2009","journal-title":"J Virol Methods"},{"key":"R11-4-20210131","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1089\/088922204323048104","article-title":"High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1.","volume":"20","author":"Richard","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R12-4-20210131","first-page":"138","article-title":"Update of the drug resistance mutations in HIV-1: December 2009.","volume":"17","author":"Johnson","year":"2009","journal-title":"Top HIV Med"},{"key":"R13-4-20210131","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1093\/bioinformatics\/bti607","article-title":"An automated genotyping system for analysis of HIV-1 and other microbial sequences.","volume":"21","author":"de Oliveira","year":"2005","journal-title":"Bioinformatics"},{"key":"R14-4-20210131","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1089\/088922204323087697","article-title":"Development of a novel human immunodeficiency virus type 1 subtyping tool, Subtype Analyzer (STAR): analysis of subtype distribution in London.","volume":"20","author":"Gale","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R15-4-20210131","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/biostatistics\/kxn018","article-title":"Sample size for positive and negative predictive value in diagnostic research using case-control designs.","volume":"10","author":"Steinberg","year":"2009","journal-title":"Biostatistics"},{"key":"R17-4-20210131","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1128\/JCM.43.8.3860-3868.2005","article-title":"Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT.","volume":"43","author":"Swanson","year":"2005","journal-title":"J Clin Microbiol"},{"key":"R18-4-20210131","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1128\/JCM.01761-08","article-title":"Evaluation of the Abbott m2000 RealTime human immunodeficiency virus type 1 (HIV-1) assay for HIV load monitoring in South Africa compared to the Roche Cobas AmpliPrep-Cobas Amplicor, Roche Cobas AmpliPrep-Cobas TaqMan HIV-1, and BioMerieux NucliSENS EasyQ HIV-1 assays.","volume":"47","author":"Scott","year":"2009","journal-title":"J Clin Microbiol"},{"key":"R19-4-20210131","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1086\/648444","article-title":"Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa.","volume":"49","author":"Hoffmann","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R20-4-20210131","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1097\/00002030-200208160-00017","article-title":"M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine.","volume":"16","author":"Ait-Khaled","year":"2002","journal-title":"AIDS"},{"key":"R22-4-20210131","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1086\/587109","article-title":"Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa.","volume":"46","author":"Marconi","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R23-4-20210131","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1128\/AAC.44.8.2109-2117.2000","article-title":"Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues.","volume":"44","author":"Van Vaerenbergh","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"R24-4-20210131","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jcv.2007.12.015","article-title":"Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.","volume":"41","author":"Sungkanuparph","year":"2008","journal-title":"J Clin Virol"},{"key":"R25-4-20210131","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1097\/QAD.0b013e32832ac34e","article-title":"The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.","volume":"23","author":"Hosseinipour","year":"2009","journal-title":"AIDS"},{"key":"R26-4-20210131","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/QAI.0b013e3181bc478b","article-title":"Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa.","volume":"53","author":"Wallis","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R27-4-20210131","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/135965350901400414","article-title":"HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme.","volume":"14","author":"Orrell","year":"2009","journal-title":"Antivir Ther"},{"key":"R28-4-20210131","doi-asserted-by":"crossref","first-page":"F9","DOI":"10.1097\/01.aids.0000232228.88511.0b","article-title":"HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.","volume":"20","author":"Brenner","year":"2006","journal-title":"AIDS"},{"key":"R29-4-20210131","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3851\/IMP1443","article-title":"Factors affecting template usage in the development of K65R resistance in subtype C variants of HIV type-1.","volume":"20","author":"Coutsinos","year":"2010","journal-title":"Antivir Chem Chemother"},{"key":"R30-4-20210131","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/00126334-200405010-00008","article-title":"Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens.","volume":"36","author":"Kuritzkes","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R31-4-20210131","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1001\/jama.296.7.782","article-title":"Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes.","volume":"296","author":"Stringer","year":"2006","journal-title":"JAMA"},{"key":"R32-4-20210131","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1089\/aid.2006.0298","article-title":"The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV\/ddI-containing HAART in southern Africa.","volume":"23","author":"Novitsky","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R33-4-20210131","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1089\/aid.2008.0180","article-title":"HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy.","volume":"24","author":"Pillay","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R34-4-20210131","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/QAD.0b013e32833677ac","article-title":"Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies.","volume":"24","author":"Vingerhoets","year":"2010","journal-title":"AIDS"},{"key":"R35-4-20210131","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/QAD.0b013e3283333639","article-title":"Outcomes after virologic failure of first-line ART in South Africa.","volume":"24","author":"Murphy","year":"2010","journal-title":"AIDS"},{"key":"R36-4-20210131","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/QAI.0b013e3181bcdac1","article-title":"High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa.","volume":"53","author":"Fox","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R37-4-20210131","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1468-1293.2010.00825.x","article-title":"Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline.","volume":"11","author":"Hosseinipour","year":"2010","journal-title":"HIV Med"},{"key":"R38-4-20210131","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1742-6405-6-30","article-title":"Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure.","volume":"6","author":"Manosuthi","year":"2009","journal-title":"AIDS Res Ther"},{"key":"R39-4-20210131","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1128\/AAC.01643-08","article-title":"Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy.","volume":"53","author":"Delaugerre","year":"2009","journal-title":"Antimicrob Agents Chemother"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00126334-201109010-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:31:53Z","timestamp":1786044713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00126334-201109010-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e318227fc34","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9,1]]}}}